title: PHARMAC's funding of 9 weeks Herceptin: many assumptions in a high-risk decision.
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Isaacs
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Frampton
authors.forename: Marion J J
authors.initials: MJ
authors.lastname: Kuper-Hommel
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D004345:Drug Industry / Q000191:economics*; D005260:Female; D006801:Humans; D009520:New Zealand; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab